The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A single-arm phase II trial of gemcitabine, oxaliplatin, and panitumumab in KRAS wild-type advanced biliary tract cancer.
Marcus Smith Noel
No relevant relationships to disclose
Jill N. Allen
No relevant relationships to disclose
Thomas Adam Abrams
No relevant relationships to disclose
Matthew Yurgelun
No relevant relationships to disclose
Jason Edward Faris
Consultant or Advisory Role - N-of-One
Lipika Goyal
No relevant relationships to disclose
Jeffrey W. Clark
No relevant relationships to disclose
Lawrence Scott Blaszkowsky
No relevant relationships to disclose
Janet E. Murphy
No relevant relationships to disclose
Hui Zheng
No relevant relationships to disclose
Alok A. Khorana
No relevant relationships to disclose
Gregory Clayton Connolly
No relevant relationships to disclose
Ollivier Hyrien
No relevant relationships to disclose
Kimmie Ng
No relevant relationships to disclose
Darrell R. Borger
No relevant relationships to disclose
Anthony John Iafrate
No relevant relationships to disclose
Aram F. Hezel
Consultant or Advisory Role - Amgen; Bayer
Andrew X. Zhu
No relevant relationships to disclose